Sustainability Report

Overview

The report presents Shanghai RAAS's first Group sustainability disclosure for 2024, covering consolidated subsidiaries and performance across the economy, environment, society, and governance. It highlights the SR604 injection entering clinical trials and receiving FDA Orphan Drug Designation, alongside 101 authorized patents and expanded healthcare access. The company reports 3,350 Group employees and 54% female employees. Environmental disclosures include 39,939.52 tCO2e of combined Scope 1 and Scope 2 emissions, 100,620.24 mWh of comprehensive energy consumption, and 3,653.34 ton of total waste generation.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services